Penn Medicine Neuromuscular Symposium 2026

Penn Medicine Neuromuscular Symposium 2026

$15

Categories: - MUS, Biologic Therapies, Genetic Therapies, Internal Medicine, Neurology, Penn Medicine (Upenn CME), Psychiatry, Uncategorized Tags: 2026 neuromuscular medicine symposium, advanced neurology course, advanced neuromuscular disease education, ALS emerging clinical trials, ALS emerging treatments, ALS novel therapies, ALS RNA targeted therapies, amyloid neuropathy treatment strategies, amyloidosis neuropathy diagnosis, amyloidosis neuropathy treatment, amyotrophic lateral sclerosis clinical trial data, amyotrophic lateral sclerosis novel therapies, chronic inflammatory demyelinating polyneuropathy diagnosis, CIDP diagnosis and treatment, CIDP treatment strategies, clinical neuromuscular symposium, clinical neuromuscular updates, CME for Neurologists, demyelinating neuropathies diagnosis, demyelinating neuropathies management, demyelinating neuropathy management, electrodiagnostic studies in neuromuscular disorders, electrodiagnostic studies neuromuscular disorders, emerging innovations in neuromuscular medicine, gene and RNA targeted therapies SMA ALS, gene therapy for hereditary myopathies, hATTR amyloidosis neuropathy, hATTR neuropathy new treatments, hereditary myopathies gene therapy, hereditary neuropathies diagnosis, hereditary neuropathies diagnosis and treatment, hereditary neuropathies treatment, hereditary neuropathy advances, hereditary transthyretin amyloidosis neuropathy, inflammatory myopathies antibody testing, inflammatory myopathies novel therapies, inflammatory myopathy antibody testing, inflammatory myopathy novel therapies, myasthenia gravis emerging therapies, myasthenia gravis mechanisms of action, myasthenia gravis novel treatments, myositis antibody testing, neurologist neuromuscular course, Neurology CME course, neurology CME neuromuscular disorders, neurology continuing medical education, neurology symposium for clinicians, neuromuscular case presentations, neuromuscular clinical case discussions, neuromuscular clinical cases, neuromuscular diagnostic reasoning, neuromuscular diagnostic studies interpretation, neuromuscular disease clinical updates, neuromuscular disease update, neuromuscular disorder management strategies, neuromuscular disorder treatment best practices, neuromuscular disorders CME, neuromuscular disorders conference, neuromuscular disorders diagnosis and management, neuromuscular gene therapy advances, neuromuscular medicine CME, neuromuscular medicine conference, neuromuscular medicine symposium, neuromuscular pulmonary management, neuromuscular respiratory complications, neuromuscular respiratory complications diagnosis, neuromuscular specialist education, neuromuscular specialist training, neuromuscular specialists CME updates, Neuromuscular Symposium 2026, neuropathy associated with amyloidosis, new treatments for hereditary neuropathies, newly approved neuromuscular therapies, novel therapies for myasthenia gravis, novel treatments in myasthenia gravis, Penn Medicine, Penn Medicine CME, Penn Medicine education, Penn Medicine neurology, Penn Medicine neurology conference, Penn Medicine neurology symposium, Penn Medicine neuromuscular, Penn Medicine neuromuscular CME, Penn Medicine neuromuscular course, Penn Medicine neuromuscular course 2026, Penn Medicine neuromuscular specialists, Penn Medicine Neuromuscular Symposium 2026, Penn Medicine neuromuscular symposium course, Penn Medicine neuromuscular update, Penn Medicine Philadelphia, Penn Neurology, Penn neurology symposium 2026, Penn Neuromuscular, Penn neuromuscular conference 2026, Penn Neuromuscular Program, Penn Neuromuscular Symposium, Penn Neuromuscular Symposium 2026, Penn Neuromuscular Symposium lectures, Penn Neuromuscular Symposium videos, Perelman School of Medicine neurology, Philadelphia neuromuscular symposium 2026, physician education neuromuscular disease, practical neuromuscular disease update, pulmonary complications in neuromuscular disease, pulmonary complications neuromuscular disease, pulmonary management in neuromuscular disorders, RNA targeted therapies neuromuscular disease, RNA targeted therapy neuromuscular disease, Rubenstein Auditorium Penn Medicine, SMA gene therapy updates, SMA RNA targeted therapies, Smilow Center Penn Medicine, Smilow Center Rubenstein Auditorium, spinal muscular atrophy novel therapies, spinal muscular atrophy novel treatments, types of demyelinating neuropathies, University of Pennsylvania neurology Brand: MedicalVideoStore

Description

Description

Include: 8 videos + 8 file sub vtt + 8 pdfs, size: 2.16 GB

Target Audience: neurologists and neuromuscular specialists

1. Overview

The annual Penn Neuromuscular Symposium is designed to provide clinicians with a comprehensive and practical update on the diagnosis and management of neuromuscular disorders. Through expert-led presentations and case-based discussions, attendees will learn how to approach a wide spectrum of neuromuscular diseases, interpret diagnostic studies, and apply current best practices in patient care. The course will also highlight recent advances in the field, including newly approved therapies and emerging innovations that are shaping the future of neuromuscular medicine.

Course Date: Saturday, March 21, 2026, 8:00 AM – 3:30 PM, Smilow Center, Rubenstein Auditorium, Philadelphia, PA

2. Learning Objectives

After completing this activity, participants should be able to:

Describe novel treatments for myasthenia gravis, including emerging therapies and their mechanisms of action.
Discuss new diagnostic approaches and treatment strategies for neuropathy associated with amyloidosis.
Discuss the different types of demyelinating neuropathies and outline current approaches to their diagnosis and management.
Describe novel treatments for spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), including recently approved therapies and emerging clinical trial data.
Describe current approaches to the diagnosis and treatment of pulmonary complications in neuromuscular diseases.
Apply antibody testing in the diagnosis of inflammatory myopathies and describe novel therapies under investigation for their treatment.
Discuss the role and recent advances of gene therapy in the treatment of hereditary myopathies.
Discuss challenging clinical cases to enhance diagnostic reasoning and management strategies in neuromuscular disorders.
Discuss recent advances in the diagnosis and treatment of hereditary neuropathies.

3. Target Audience

Best for neurologists and neuromuscular specialists who want updates on gene therapies, myasthenia gravis treatments, and neuropathies.

4. Topics

Advances in Gene- and RNA-Targeted Therapies for SMA and ALS
Antibody Testing and Novel Therapies in Inflammatory Myopathies
Diagnosing and Managing Demyelinating Neuropathies
Hereditary Neuropathies, Including hATTR – New Insights and Treatments
How to Incorporate Novel Treatments in Myasthenia Gravis
Neuromuscular Case Presentation – 01
Neuromuscular Case Presentation
Welcome